The Effect of Meal Replacement on the Time to Reach the Blood Glucose Target in Patients With Type 2 Diabetes Mellitus

NCT05365152 | Unknown

• 1 other identifier: 2021-793
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study was designed as a randomized controlled study. It was planned to include 100 patients with type 2 diabetes who received short-term intensive insulin therapy and randomly divided them into a meal replacement intervention group and a conventional diabetes diet group according to 1:1. Both groups were treated with short-term intensive insulin therapy to control blood sugar. .

Conditions

Diabetes; Blood Sugar; High

Keywords

type 2 diabetes; Meal Replacement

Outcome Measures

Primary Outcomes (1)

• Time required for blood sugar to reach target

  The time it takes for the patient to reach the prescribed glycemic control goals during the hospital stay

  7-10days

Study Arms (2)

Meal replacement intervention group

EXPERIMENTAL

On the day of the patient's admission, the total calories required for the diabetic diet during the hospitalization period were calculated according to "ideal weight \* 25/kcal" (BMI \> 28, 80% of this value). Carbohydrates, fats, and proteins accounted for 50%, 30%, and 20% of the energy supply, respectively, and the calories of the three meals were distributed according to 1:2:2. The meal replacement intervention group replaced the daily meal with meal replacement on the basis of the conventional diabetic diet. About 400kcal calories in carbohydrates.

Dietary Supplement: Meal Replacement

diabetes diet group

NO INTERVENTION

On the day of the patient's admission, the total calories required for the diabetic diet during the hospitalization period were calculated according to "ideal weight \* 25/kcal" (BMI \> 28, 80% of this value). Carbohydrates, fats, and proteins accounted for 50%, 30%, and 20% of the energy supply, respectively, and the calories of the three meals were distributed according to 1:2:2.

Interventions

Meal Replacement DIETARY_SUPPLEMENT

Meal Replacement

Meal replacement intervention group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Type 2 diabetic patients who meet the diagnosis of type 2 diabetes (CDS2020) and are willing to receive intensive insulin hypoglycemic therapy;
• Glycated hemoglobin A1c≥7.5%;
• Age between 18-70 years old, body mass index (BMI) 20-35kg/m2;
• Be able and willing to cooperate with diet and exercise and monitor blood sugar in accordance with the project regulations, and agree to sign the informed consent.

You may not qualify if:

• Diagnosed as type 1 diabetes or special type of diabetes;
• Allergic or intolerable to the meal replacement food used in the study;
• Acute complications of diabetes (including DKA, HHS, lactic acidosis)
• Severe microvascular complications: proliferative retinopathy; urine AER\>300mg/g or urine protein positive, quantitative\>0.5g/d; uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy;
• Significant macrovascular complications: patients with acute cerebrovascular accident, acute coronary syndrome, peripheral arterial disease requiring vascular intervention or amputation within 12 months before enrollment;
• Serum creatinine clearance rate is less than 50ml/min/1.73m2 (calculated according to CKDEPI formula), alanine aminotransferase ≥ 3 times the upper limit of normal, and total bilirubin ≥ 2 times the upper limit of normal;
• The cumulative time of using drugs that may affect blood sugar for more than 1 week within 12 weeks, such as oral/intravenous glucocorticoids, GH, estrogen/progestin, high-dose diuretics, antipsychotics, etc.;
• Systemic infection or serious concomitant diseases; patients with malignant tumors or chronic diarrhea;
• Uncontrolled endocrine gland dysfunction;
• Mental or communication disorders;
• Pregnant and lactating women;
• The subject is not cooperative, or the investigator judges that it may be difficult to complete the investigator;

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (1)

the First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510000, China

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus; Hyperglycemia; Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: CARE PROVIDER
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: chief physician

Study Record Dates

• First Submitted: April 14, 2022
• First Posted: May 9, 2022
• Study Start: April 1, 2022
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: May 9, 2022

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)